Description | The antibody CV07-250 is a human mAb specific for SARS-CoV-2 Spike S1 protein. The strongest neutralizing mAb reduced ACE2 binding to the RBD to 58.3%. The binding mode of antibody to the RBD is unusual in that it is dominated by the light chain. It uses CDR H1, H3, L1, and L3 and framework region 3 (LFR3) for RBD interaction. It (IC50 = 3.5 ng/mL) had 33 SHMs (17/16 on the heavy and light chain, respectively) and strongly reduced ACE2 binding and showed no binding to murine tissue. |
Clonality | Monoclonal |
Host Species | Human |
Target Species | SARS-CoV-2 |
Epitope | Receptor-binding domain (RBD) |
Isotype | IgG1 |
Expression Species | HEK293F or CHO cell line |
Conjugation | Unconjugated |
Purity | >95% |
Endotoxin | <1 EU/mg |
Form | Liquid |
Purification | Protein A purified |
Sterility | 0.2 μM filtered |
Formulation | PBS, pH 7.4 |
Preservation | No preservatives |
Stabilizer | No stabilizers |
Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
Application | ELISA, Neut |
Application Notes | The IC50 value of CV07-250 is 3.5 ng/mL. |
ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
WB | Western Blot Protocol |
FC | Western Blot Protocol |
Target | SARS-CoV-2 |
Alternative Name | Severe acute respiratory syndrome coronavirus 2 |
Research Area | Coronavirus Disease 2019 |
Related Disease | Coronavirus Disease 2019 |